← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2003First marketed drug
May 25, 2002First NDA
Sep 11, 2009Last known activity
Jun 27, 2023
Timeline
1990s
- Jan 1, 1996
Theravance— Founded
2010s
- Nov 9, 2018
revefenacin— NDA Organization
Drugs by trial phase (33 distinct, 79 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (7 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (12 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Alzheimer Disease
- Asthma
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Bacteremia
- Bacterial Infections
- Cellulitis
- Colitis
- Colitis, Ulcerative
- Communicable Diseases
- Constipation
- Critical Illness
- Crohn Disease
- Cystic Fibrosis
- Disease
- Fibromyalgia
- Fibrosis
- Gastroparesis
- Gram-Positive Bacterial Infections
- Healthcare-Associated Pneumonia
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hyperkinesis
- Hypertension
- Hypotension
- Hypotension, Orthostatic
- Idiopathic Pulmonary Fibrosis
- Infections
- Inflammation
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Kidney Diseases
- Kidney Failure, Chronic
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Injury
- Multiple System Atrophy
- Myofascial Pain Syndromes
- Parkinson Disease
- Pneumonia
- Pneumonia, Bacterial
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Fibrosis
- Pulmonary Valve Insufficiency
- Pure Autonomic Failure
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Respiratory Aspiration
- Respiratory Distress Syndrome
- Respiratory Insufficiency
- Shy-Drager Syndrome
- Skin Diseases, Infectious
- Staphylococcal Infections
- Staphylococcal Skin Infections
- Ulcer
- Wound Infection
Marketed drugs (2)
Recent trials (50)
- NCT05696717Lead sponsorPhase 3Jun 27, 2023
- NCT05165485Lead sponsorPhase 4Dec 31, 2021
- NCT05165485Study directorPhase 4Dec 31, 2021
- NCT05091723Study directorPhase 1Oct 13, 2021
- NCT05091723Lead sponsorPhase 1Oct 13, 2021
- NCT04688632Lead sponsorPhase 1Jan 18, 2021
- NCT04688632Study directorPhase 1Jan 18, 2021
- NCT04587713Lead sponsorPhase 1Oct 16, 2020
- NCT04587713Study directorPhase 1Oct 16, 2020
- NCT04589260Lead sponsorPhase 1Oct 15, 2020
- NCT04589260Study directorPhase 1Oct 15, 2020
- NCT04402866Study directorPhase 2May 31, 2020
- NCT04402866Lead sponsorPhase 2May 31, 2020
- NCT04350736Lead sponsorPhase 1Apr 30, 2020
- NCT04315558CollaboratorPhase 2Apr 30, 2020
Details
- Founded
- South San Francisco, CA, US Jan 1, 1996
- First NDA
- Sep 11, 2009
- Last known activity
- Jun 27, 2023